Evaluation of BRCA1 and BRCA2 as Indicators of Response to Immune Checkpoint Inhibitors.

doi:10.1001/jamanetworkopen.2021.7728

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Evaluation of BRCA1 and BRCA2 as Indicators of Response to Immune Checkpoint Inhibitors.

JAMA network open - 3 May 2021

Zhou Zhijun, Li Min

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to BRCA1 Protein
Share to BRCA2 Protein
Share to Cohort Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Kaplan-Meier Estimate

Share to Mutation

Share to Tumor Burden

Source

Open in PubMed Open full text

Identifiers

PMID: 33961040
DOI: 10.1001/jamanetworkopen.2021.7728
PMCID: PMC8105747

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Evaluation of BRCA1 and BRCA2 as Indicators of Response to Immune Checkpoint Inhibitors.PMID 33961040Read ↗

Predictive biomarkers for response to immune checkpoint inhibitionSemantic proximity Read ↗

Predictive biomarkers for hyper-progression (HP) in response to immune checkpoint inhibitors (ICI) – analysis of somatic alterations (SAs)Semantic proximity Read ↗

MDM2/4 amplification predicts poor response to immune checkpoint inhibitors: a pan-cancer analysisSemantic proximity Read ↗

Study finds different treatment responses between BRCA2- and BRCA1-mutated ovarian cancers.Semantic proximity Read ↗

Biomarkers of response to PD-1 pathway blockadeSemantic proximity Read ↗

Biomarkers to tailor chemoradiation therapies.Semantic proximity Read ↗

Summaries for patients. Validity of models for predicting BRCA1 and BRCA2 mutations.Semantic proximity Read ↗

Genomic correlates of response to immune checkpoint blockadeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.